In August 2011, “Recanemab” was approved as a treatment for Alzheimer’s disease, and the drug price was set at 2.98 million yen per year (for a person weighing 50 kg). It is attracting worldwide attention for slowing the progression of symptoms, but this does not solve all dementia problems (PHOTO: AFRO)
In the age of retirement at 65… “Juvenile Dementia” in the working-age population can be improved with early treatment.
|NEWS